• Return to Headlines

Relatively Low EBITDA Growth Detected in Shares of Vanda Pharmaceuticals in the Biotechnology Industry (VNDA, SVA, EBS, GILD, BIIB)

By David Diaz

Below are the three companies in the Biotechnology industry with the lowest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

Vanda Pharmaceuticals ranks lowest with a EBITDA growth of -74.8%. Following is Sinovac Biotech with a EBITDA growth of -40.0%. Emergent Biosolutions ranks third lowest with a EBITDA growth of -24.7%.

Gilead Sciences follows with a EBITDA growth of -0.1%, and Biogen Idec rounds out the bottom five with a EBITDA growth of 9.4%.

SmarTrend recommended that its subscribers protect gains by selling shares of Emergent Biosolutions on June 16th, 2016 by issuing a Downtrend alert when the shares were trading at $40.80. Since that call, shares of Emergent Biosolutions have fallen 26.4%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: lowest ebitda growth vanda pharmaceuticals amex:sva sinovac biotech emergent biosolutions Gilead Sciences Biogen Idec